India's Serum Institute applies for full approval of Covishield vaccine

BENGALURU (Reuters) - Serum Institute Of India has applied to the country's drug regulator and the health ministry for full market authorisation of its COVID-19 vaccine, Covishield, the company's chief executive said in a tweet on Friday.

Serum Institute produces AstraZeneca's COVID-19 vaccine under the brand name Covishield.

(Reporting by Shivani Singh in Bengaluru; Editing by Shounak Dasgupta)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting